Weiguo Qing
Impact in
- Oncology top 5%
- Cancer-related Molecular Pathways
- Hepatology top 10%
- Liver physiology and pathology
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 3
- Protein Degradation and Inhibitors 2
- Oncology 9
- Colorectal Cancer Treatments and Studies 2
- Co-authors
- James Rosinski (1 shared paper)Binh Thanh Vu (1 shared paper)Lyubomir T. Vassilev (1 shared paper)Zoran Filipovic (1 shared paper)David Heimbrook (1 shared paper)Xiaolan Zhao (1 shared paper)Brian Higgins (1 shared paper)Kathryn Packman (1 shared paper)
- Journals
- Cancer Research (9 papers)Oncotarget (2 papers)Molecular Cancer Therapeutics (2 papers)Journal of Medicinal Chemistry (1 paper)Toxicology (1 paper)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Weiguo Qing
22 papers receiving 801 citations
Weiguo Qing's Hit Papers
Peers
Comparison fields: 5 of 70
- Oncology 405
- Hepatology 61
- Cancer Research 104
- Biotechnology 64
- Molecular Biology 488
Countries citing papers authored by Weiguo Qing
This map shows the geographic impact of Weiguo Qing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiguo Qing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiguo Qing more than expected).
Fields of papers citing papers by Weiguo Qing
This network shows the impact of papers produced by Weiguo Qing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiguo Qing. The network helps show where Weiguo Qing may publish in the future.
Co-authors
The 25 scholars most cited alongside Weiguo Qing, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy Hit paper breakdown → | 2006 | 556 |
| 2 | 2014 | 115 | |
| 3 | 2016 | 27 | |
| 4 | 2011 | 22 | |
| 5 | 2019 | 16 | |
| 6 | 1996 | 13 | |
| 7 | 1998 | 12 | |
| 8 | 1995 | 8 | |
| 9 | 2017 | 6 | |
| 10 | 2014 | 6 | |
| 11 | 2011 | 5 | |
| 12 | 2013 | 4 | |
| 13 | 2023 | 3 | |
| 14 | 2022 | 3 | |
| 15 | 2017 | 3 | |
| 16 | 2013 | 2 | |
| 17 | Construction of immune cell infiltration score model to assess prognostic ability of tumor immune environment in lung adenocarcinoma. | 2023 | 2 |
| 18 | 2023 | 2 | |
| 19 | 2016 | 1 | |
| 20 | 2023 | 1 |
About Weiguo Qing
Weiguo Qing is a scholar working on Molecular Biology, Oncology, Hepatology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 809 indexed citations. Recurring topics across this work include Liver physiology and pathology (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Lung Cancer Treatments and Mutations (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Protein Degradation and Inhibitors (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Mechanisms and Therapy (2 papers). The work is most often cited by research in Oncology (405 citations), Hepatology (61 citations), Cancer Research (104 citations), Biotechnology (64 citations) and Molecular Biology (488 citations). Weiguo Qing has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include James Rosinski, Binh Thanh Vu, Lyubomir T. Vassilev, Zoran Filipovic, David Heimbrook, Xiaolan Zhao, Brian Higgins, Kathryn Packman, Holly Hilton and Ola Myklebost. Their work appears in journals such as Cancer Research, Oncotarget, Molecular Cancer Therapeutics, Journal of Medicinal Chemistry and Toxicology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.